Advertisement
Screener

Biofrontera Inc. (BFRI) Restructuring Costs

2.8 / 5 stars · 68/120 Roast Me

Biofrontera Inc. Restructuring Costs

Biofrontera Inc. (BFRI) reported Restructuring Costs of $0 for the 12-month period ending 2022-12-31, per its 8-K filed 2023-10-03.

Discontinued › Cash Flow › Other Cash Flow Items

us-gaap:RestructuringCosts · last filed 2023-10-03

  • Biofrontera Inc. restructuring costs for the quarter ending 2022-12-31 was $0.00, a 100.00% decline year-over-year.
  • Biofrontera Inc. restructuring costs for the quarter ending 2022-09-30 was $0.00, a 100.00% decline year-over-year.
  • Biofrontera Inc. restructuring costs for the quarter ending 2022-06-30 was $0.00, a 100.00% decline year-over-year.
  • Biofrontera Inc. restructuring costs for the quarter ending 2022-03-31 was $0.00, a 100.00% decline year-over-year.
  • Biofrontera Inc. restructuring costs for fiscal 2020 was $1.10M.
Period endRestructuring Costs 3 monthRestructuring Costs 3 month as first filedRestructuring Costs 6 monthRestructuring Costs 9 monthRestructuring Costs 9 month as first filedRestructuring Costs 12 month
2022-12-31$0.00
derived: 8-K 12 month − 10-Q 9 month · filed 2023-10-03
$0.00
derived: sum of 2 quarters · filed 2023-10-03
$0.00
derived: sum of 3 quarters · filed 2023-10-03
$0.00
8-K · filed 2023-10-03
2022-09-30$0.00
10-Q · filed 2022-11-14
$0.00
derived: sum of 2 quarters · filed 2022-11-14
$0.00
10-Q · filed 2022-11-14
$100.00K
derived: sum of 4 quarters · filed 2023-10-03
2022-06-30$0.00
10-Q · filed 2022-08-12
$0.00
10-Q · filed 2022-08-12
$100.00K
derived: sum of 3 quarters · filed 2023-10-03
$300.00K
derived: sum of 4 quarters · filed 2023-10-03
2022-03-31$0.00
10-Q · filed 2022-05-13
$100.00K
derived: sum of 2 quarters · filed 2023-10-03
$300.00K
derived: sum of 3 quarters · filed 2023-10-03
$800.00K
derived: sum of 4 quarters · filed 2023-10-03
2021-12-31$100.00K
derived: 8-K 12 month − 10-Q 9 month · filed 2023-10-03
$300.00K
derived: sum of 2 quarters · filed 2023-10-03
$800.00K
derived: sum of 3 quarters · filed 2023-10-03
$800.00K
8-K · filed 2023-10-03
2021-09-30$200.00K
10-Q · filed 2022-11-14
$199.00K
10-Q · filed 2021-11-30
$700.00K
derived: sum of 2 quarters · filed 2022-11-14
$700.00K
10-Q · filed 2022-11-14
$654.00K
10-Q · filed 2021-11-30
$1.24M
derived: sum of 4 quarters · filed 2022-11-14
2021-06-30$500.00K
10-Q · filed 2022-08-12
$500.00K
10-Q · filed 2022-08-12
$1.04M
derived: sum of 3 quarters · filed 2022-08-12
$1.22M
derived: sum of 4 quarters · filed 2022-08-12
2021-03-31$300.00K
10-Q · filed 2022-05-13
$539.00K
derived: sum of 2 quarters · filed 2022-05-13
$720.00K
derived: sum of 3 quarters · filed 2022-05-13
2020-12-31$239.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-04-11
$420.00K
derived: sum of 2 quarters · filed 2022-04-11
$1.10M
10-K · filed 2022-04-11
2020-09-30$181.00K
10-Q · filed 2021-11-30
$861.00K
10-Q · filed 2021-11-30

Similar stocks

Stock NameCountryMarket CapPE Ratio
Lipocine Inc. (LPCN)United States$0.017B-1.79
PALATIN TECHNOLOGIES INC (PTN)United States$0.017B-5.36
Allarity Therapeutics, Inc. (ALLR)United States$0.017B-1.66
Pasithea Therapeutics Corp. (KTTA)United States$0.017B-0.81
Rocket One Inc. (RKTO)United States$0.019B
Shuttle Pharmaceuticals Holdings, Inc. (SHPH)United States$0.019B-0.31
Cellectar Biosciences, Inc. (CLRB)United States$0.020B-1.03
Marker Therapeutics, Inc. (MRKR)United States$0.020B-2.86
Neuphoria Therapeutics Inc. (NEUP)United States$0.020B-1.77
Korsana Biosciences, Inc. (CYCN)United States$0.016B